Developer docs
API playgroundTry for free, no card

Search company profiles

Rafa Laboratories Ltd.

Full company profile

uuid000884u

Namestring
Rafa Laboratories Ltd.
Legal namestring
מעבדות רפא בע"מ (Rafa Laboratories Ltd.)
Company typeenum
Private
Founded yearint
1937
Descriptiontext

Rafa Laboratories Ltd. is a privately held Israeli pharmaceutical company founded in 1937 and headquartered in Jerusalem. With 101–250 employees, the company manufactures and distributes originator drugs, generics, prescription medications, OTC products, and therapeutic products through a GMP-compliant facility certified to EMA standards and holds ISO 27001 certification. Its portfolio spans multiple therapeutic categories, including Hedrin (lice treatment), Monurol (UTI), Tesalin (plant-based allergy medicine), Cimidona (menopause), Prefemin (PMS), Kelocote (scar treatment), and Betadine, and it markets the Axiban medical cannabis product via a manufacturing partnership with Panaxia.

The company serves the Israeli healthcare market with products reaching all healthcare institutions — hospitals, pharmacies, and the four national health funds — and supplements domestic distribution with international in-licensing and out-licensing partnerships with FAES FARMA, FALK, HELSINN, ONY Biotech, Sinclair, T&R, United Therapeutics, Zambon, Zeller, and Epitomee. In December 2021, Rafa became the first Israeli pharma to implement medical cannabis home delivery through a partnership with Maccabi Health Services. In August 2022, the company acquired a strategic stake in ExCEEd Orphan, extending its footprint into rare-disease therapeutics across Central and Eastern Europe.

Rafa's business model combines multi-channel pharmaceutical distribution within Israel, export and licensing partnerships abroad, and selective product innovation, including 10+ product launches between 2015 and 2025. Leadership transitioned to Ido Leshem as CEO in January 2024, signaling continuity of strategy with incremental expansion into adjacent categories such as rare diseases and medical cannabis.

Short descriptiontext

Rafa Laboratories is a privately held Israeli pharmaceutical company founded in 1937, manufacturing originator drugs, generics, prescription meds, and OTC products through a GMP/EMA-certified facility and serving hospitals, pharmacies, and health funds across Israel.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersJerusalem, Israel
HQ citystring
Jerusalem
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical manufacturing, generic medicines, over-the-counter drugs, medical cannabis products, prescription medications
Industry2 codes
1Adult-Use (Recreational) Cannabis Delivery & Online Ordering
CodeCRANAGAHPrimaryNo
2CBD/Hemp Wellness & Supplements Retail
CodeCRANAHACPrimaryNo
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Medicinal and Botanical Manufacturing325411
SIC code2 codes
  • Medicinal Chemicals & Botanical Products2833
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Pharmaceuticals
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Rafa Laboratories generates revenue through the sale of originator drugs, generic drugs, prescription medications, OTC products, and therapeutic products. The company markets a wide range of medicines and therapeutic preparations that help thousands of infants, children, adults, and elderly in Israel daily. Products are distributed through pharmacies, hospitals, and healthcare institutions.

rafa.co.il
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 11 records shown
1Hedrin (הדרין)
Description

Product line for head lice treatment including gel, spray, and mousse variants.

rafa.co.il
+10 more records
Core offering1 text field

Rafa Laboratories is an Israeli pharmaceutical company that manufactures, markets, and distributes a broad portfolio of originator drugs, generic medicines, prescription pharmaceuticals, OTC products, and medical cannabis products. The company operates a GMP-compliant manufacturing facility in Jerusalem compliant with European EMA regulations and distributes products across all Israeli healthcare institutions, pharmacies, and online channels. Its portfolio spans anti-infectives, respiratory/allergy, gastroenterology, pain management, dermatology, women's health, pediatrics, weight management, and medical cannabis therapeutic areas.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Rafa Laboratories Ltd. (מעבדות רפא בע"מ) is an Israeli pharmaceutical company founded in 1937, specializing in the marketing, manufacturing, and distribution of originator medicines, generic drugs, prescription pharmaceuticals, over-the-counter (OTC) medicines, and therapeutic products. The company's product portfolio is organized into therapeutic categories spanning: anti-infectives (Coliracin, Itranol, Flucanol, Pen-Rafa VK, Monurol, Betadine); respiratory/allergy (Tesalin for allergic rhinitis); gastroenterology; pain management (Kalgaron lozenges, Nervo3 gel for neuropathic pain); dermatology and wound care (Betadine spray, Kelocote scar gel); women's health (Cimidona for menopause, Prefemin for PMS, Folex 400 for iron-deficiency anemia in pregnancy); medical cannabis (Axiban sublingual drops in 5 THC/CBD concentrations, IMC Medical Grade); pediatric health (Hedrin lice treatment line with gel, spray, mousse, and protect spray); and weight management (Epitomee Capsule). Rafa also operates a GMP-compliant manufacturing facility in Jerusalem and distributes its products across all healthcare institutions and pharmacies in Israel.

Product and service17 records
1Coliracin (קולירצין)
CategoryPrescription Drug - Anti-infective
Description

Antibiotic for treating infections caused by bacteria sensitive to colistin. Supplied as powder for infusion concentrate, containing 1,000,000 units of colistimethate sodium per vial. For healthcare institutions.

2Itranol (איטרנול)
CategoryPrescription Drug - Antifungal
Description

Antifungal medication in capsule form (itraconazole 100 mg) for treating fungal infections of the mouth, throat, esophagus, vagina, skin, and nails, and systemic mycosis. For healthcare institutions and patients.

3Flucanol (פלוקנול)
CategoryPrescription Drug - Antifungal
Description

Antifungal medication in capsules (fluconazole 50/100/150/200 mg) for treating a broad range of fungal infections including cryptococcal meningitis, candidiasis, oral/vaginal thrush, skin fungal infections, and for prevention of fungal infections in immunocompromised patients.

4Pen-Rafa VK 500 (פן-רפא וי-ק 500)
CategoryPrescription Drug - Antibiotic
Description

Penicillin-based antibiotic in capsules (penicillin V as potassium 500 mg) for treating infections caused by penicillin-sensitive bacteria. For healthcare institutions and patients.

5Betadine Topical Spray (בטאדין תרסיס לשימוש חיצוני)
CategoryOTC Drug - Antiseptic
Description

Topical powder spray antiseptic (povidone iodine 2.5%) for skin disinfection, treatment and prevention of infections from burns, cuts, and surgical wounds. Non-stinging, creates a dry layer. OTC product for consumers.

6Monurol (מונורול)
CategoryPrescription Drug - Antibiotic
Description

Antibiotic powder (fosfomycin trometamol 3 g) for treating acute uncomplicated cystitis in women and adolescent girls, and for preventive antibiotic treatment prior to transrectal prostate biopsy in adult men. Prescription drug for healthcare institutions and patients.

7Kalgaron (קלגרון)
CategoryOTC Drug - Throat Care
Description

Sore throat lozenges (cetylpyridinium chloride 1.25 mg and lidocaine hydrochloride 1 mg) for relief of severe sore throat and oral/pharyngeal infections. Available in strawberry, mint, and orange flavors. For adults and children from age 6. OTC consumer product.

8Cimidona 6.5 mg (סימידונה 6.5 מ"ג)
CategoryOTC Drug - Women's Health
Description

Tablet containing 6.5 mg of black cohosh (Cimicifuga) dry extract for relief of menopausal symptoms including hot flashes, excessive sweating, sleep disturbances, irritability, and depressive mood. OTC product for consumers.

9Cimidona Forte 13 mg (סימידונה פורטה 13 מ"ג)
CategoryPrescription Drug - Women's Health
Description

Tablet containing 13 mg of black cohosh (Cimicifuga) dry extract for relief of menopausal symptoms including hot flashes, excessive sweating, sleep disturbances, irritability, and depressive mood. Prescription drug for healthcare institutions and patients.

10Prefemin (פרפמין)
CategoryOTC Drug - Women's Health
Description

Tablet containing 20 mg of Agnus Castus (Agni Casti) dry extract for treatment of premenstrual syndrome (PMS) in women over 18. Hormone-free; relieves both emotional and physical PMS symptoms including mood changes, irritability, headaches, and breast congestion. OTC product for consumers.

11Folex 400 (פולקס 400)
CategoryOTC Drug - Women's Health / Hematology
Description

Tablets containing ferrous fumarate 100 mg and folic acid 400 mcg for prevention and treatment of iron-deficiency anemia and maintenance of folic acid levels, especially during pregnancy. OTC product for consumers.

12Tesalin (טסלין)
CategoryOTC Drug - Allergy / Respiratory
Description

Tablet containing 8 mg of petasins extracted from Petasites hybridus leaves for treatment of allergic rhinitis (hay fever) symptoms and associated eye, nose, and throat symptoms. Free of steroids and antihistamines, non-sedating, suitable from age 12. OTC product for consumers.

13Axiban (אקסיבן)
CategoryPrescription Drug - Medical Cannabis
Description

Medical cannabis product in full extract form with precise, standardized THC and CBD concentrations. Available as sublingual drops in 5 concentration combinations (T15/C3, T10/C10, T3/C15, T1/C20, T22/C4), each bottle containing 10 grams total. Requires a medical cannabis license. Manufactured under IMC Medical Grade standards. For licensed medical cannabis patients.

14Epitomee Capsule (קפסולת אפיטומי)
CategoryMedical Device - Weight Management
Description

Capsule for weight management in adults with overweight or obesity (BMI 25-40 kg/m²), used in combination with a balanced diet and physical exercise. Works via a mechanical mechanism (no active pharmaceutical ingredient). OTC consumer product.

15Hedrin Product Line (הדרין)
CategoryOTC Drug - Pediatric / Consumer Health
Description

Complete line of OTC products for the treatment and prevention of head lice. Includes: Hedrin ONCE Gel (15-minute single-treatment for short to medium hair), Hedrin ONCE Spray (for long/curly hair), Hedrin & Go Mousse (no immediate shampooing required), Hedrin Protect Spray (lice prevention, clinically proven), and Hedrin Wash Shampoo. All based on a physical mode of action without chemical pesticides, approved from age 6 months. For consumers and parents.

16Kelocote Product Line (קלו-קוט)
CategoryOTC Drug / Medical Device - Dermatology
Description

Silicone gel-based scar treatment product line. Includes: Kelocote Gel Tube (for all scar types except depressed scars), Kelocote Gel Spray (for widespread or touch-sensitive scars), and Kelocote UV Gel (with sun protection). Softens, flattens, and reduces redness of raised scars; relieves itch, pain, and discomfort. Clinically proven; recommended by physicians and pharmacists. For consumers and healthcare institutions.

17Nervo3 Gel (נרבו 3 ג'ל)
CategoryOTC Drug - Pain Management / Neurology
Description

Topical gel for treatment of neuropathic symptoms (damage to the peripheral nervous system) of inflammatory, metabolic, or infectious origin. Contains a stabilized ozone formulation in oleic acid with alpha-lipoic acid, vitamin E acetate, capsicum extract, and essential amino acids. Clinically proven; available without prescription. For consumers and healthcare institutions.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-08-01
Description

Rafa Laboratories is acquiring a significant stake in ExCEEd Orphan to improve its capabilities and expand its portfolio in medicines for rare diseases in CEE (Central and Eastern Europe) and Israel. The collaboration aims to bring new orphan drugs to these markets, driven by increasing demand and growth in the global orphan drug market. The partnership reflects Rafa's strategy to become an international player in this niche sector.

Strategic tierCoreTypeTechnology or Integration
Description

Panaxia is the manufacturer producing medical cannabis products for Rafa. Panaxia received Ministry of Health license to manufacture medical cannabis pharmaceutical products under GMP conditions and manufactures and sells medical cannabis products in various countries including the USA.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Epitomee capsule for weight management distributed by Rafa in Israel. Medical device/cosmetic product for adults with overweight or obesity (BMI 25-40 kg/m²) in combination with diet and physical activity.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

International pharmaceutical company whose products are distributed by Rafa in the Israeli market.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

International pharmaceutical company whose products are distributed by Rafa in the Israeli market.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

International pharmaceutical company whose products are distributed by Rafa in the Israeli market.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Biotechnology company whose products are distributed by Rafa in the Israeli market.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

International pharmaceutical company whose products are distributed by Rafa in the Israeli market.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

International pharmaceutical company whose products are distributed by Rafa in the Israeli market.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

International pharmaceutical company focused on pulmonary hypertension whose products are distributed by Rafa in the Israeli market.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

International pharmaceutical company whose products are distributed by Rafa in the Israeli market.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

International pharmaceutical company whose products are distributed by Rafa in the Israeli market.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Rafa and Maccabi Yozmot and Management signed an agreement for supply of quality medical cannabis products from Rafa to Maccabi Healthcare members. The products are delivered directly to Maccabi members' homes, making Rafa the first Israeli pharmaceutical company to implement the medical cannabis reform.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Israel's largest pharmaceutical company and the world's leading generic drug manufacturer. Directly comparable to Rafa as a domestic Israeli pharma with branded generics, OTC, and specialty portfolios, though operating at much larger global scale.

TypeDirect peer
Description

Israel-based generic pharmaceutical manufacturer with a focus on branded generics, OTC, and prescription products. Direct competitor in the Israeli generic pharma space with overlapping therapeutic categories such as dermatology and anti-infectives.

TypeDirect peer
Description

Israeli specialty pharmaceutical company developing and marketing branded generic and innovative medicines. Comparable mid-sized peer with a similar Israel-centric go-to-market model and therapeutic breadth.

TypeRegional player
Description

Israeli pharmaceutical manufacturer and marketer focused on generic and branded generic products distributed across Israeli pharmacies. Comparable in therapeutic scope and channel strategy to Rafa's portfolio.

TypeDirect peer
Description

Israeli pharmaceutical-grade medical cannabis manufacturer that produces Axiban for Rafa under GMP. Comparable in the cannabis-pharma intersection with overlapping manufacturing standards (IMC Medical Grade, GMP).

TypeBroad incumbent
Description

Global leader in consumer self-care products and generic pharmaceuticals with strong OTC and store-brand portfolios. Comparable to Rafa's OTC and consumer health segments (e.g., Hedrin, Kalgaron, Betadine, Tesalin).

TypeDirect peer
Description

Swiss specialty pharmaceutical company focused on cancer supportive care and rare diseases. Already partners with Rafa for Israeli distribution; comparable as a mid-size specialty pharma expanding through regional partnerships.

TypeBroad incumbent
Description

U.S. biotechnology company specializing in pulmonary hypertension products distributed by Rafa in Israel. Comparable therapeutic-area overlap in respiratory and pulmonary arterial hypertension.

TypeDirect peer
Description

Spanish pharmaceutical company with branded generics, OTC, and specialty products. Distributes through Rafa in Israel and shares a comparable mid-cap specialty pharma profile with international partnership-driven growth.

TypeDirect peer
Description

Italian multinational pharmaceutical company with focus on respiratory, pain, and women's health. Comparable to Rafa's therapeutic portfolio breadth and partnership-based international expansion model.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Rafa Laboratories Ltd.

Pharmaceuticalsrafa.co.il

Rafa Laboratories is a privately held Israeli pharmaceutical company founded in 1937, manufacturing originator drugs, generics, prescription meds, and OTC products through a GMP/EMA-certified facility and serving hospitals, pharmacies, and health funds across Israel.

What Rafa Laboratories Ltd. does

Rafa Laboratories Ltd. is a privately held Israeli pharmaceutical company founded in 1937 and headquartered in Jerusalem. With 101–250 employees, the company manufactures and distributes originator drugs, generics, prescription medications, OTC products, and therapeutic products through a GMP-compliant facility certified to EMA standards and holds ISO 27001 certification. Its portfolio spans multiple therapeutic categories, including Hedrin (lice treatment), Monurol (UTI), Tesalin (plant-based allergy medicine), Cimidona (menopause), Prefemin (PMS), Kelocote (scar treatment), and Betadine, and it markets the Axiban medical cannabis product via a manufacturing partnership with Panaxia.

The company serves the Israeli healthcare market with products reaching all healthcare institutions — hospitals, pharmacies, and the four national health funds — and supplements domestic distribution with international in-licensing and out-licensing partnerships with FAES FARMA, FALK, HELSINN, ONY Biotech, Sinclair, T&R, United Therapeutics, Zambon, Zeller, and Epitomee. In December 2021, Rafa became the first Israeli pharma to implement medical cannabis home delivery through a partnership with Maccabi Health Services. In August 2022, the company acquired a strategic stake in ExCEEd Orphan, extending its footprint into rare-disease therapeutics across Central and Eastern Europe.

Rafa's business model combines multi-channel pharmaceutical distribution within Israel, export and licensing partnerships abroad, and selective product innovation, including 10+ product launches between 2015 and 2025. Leadership transitioned to Ido Leshem as CEO in January 2024, signaling continuity of strategy with incremental expansion into adjacent categories such as rare diseases and medical cannabis.

Rafa Laboratories Ltd. firmographics

Firmographics
Name
Rafa Laboratories Ltd.
Legal name
מעבדות רפא בע"מ (Rafa Laboratories Ltd.)
Website
https://www.rafa.co.il
Company type
Private
Founded year
1937
Operating status
Operating
Headcount range
101–250 employees
Short description
Rafa Laboratories is a privately held Israeli pharmaceutical company founded in 1937, manufacturing originator drugs, generics, prescription meds, and OTC products through a GMP/EMA-certified facility and serving hospitals, pharmacies, and health funds across Israel.
Ownership category
akta.pro rank

Where Rafa Laboratories Ltd. is headquartered

Location

Headquarters

HQ city
Jerusalem
HQ country
Israel
HQ region
Middle East

Offices2 records

Markets served

Rafa Laboratories Ltd. business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Product Sales: Rafa Laboratories generates revenue through the sale of originator drugs, generic drugs, prescription medications, OTC products, and therapeutic products. The company markets a wide range of medicines and therapeutic preparations that help thousands of infants, children, adults, and elderly in Israel daily. Products are distributed through pharmacies, hospitals, and healthcare institutions.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels3 records

Rafa Laboratories Ltd. product offering

Product offering

Core offering

Rafa Laboratories is an Israeli pharmaceutical company that manufactures, markets, and distributes a broad portfolio of originator drugs, generic medicines, prescription pharmaceuticals, OTC products, and medical cannabis products. The company operates a GMP-compliant manufacturing facility in Jerusalem compliant with European EMA regulations and distributes products across all Israeli healthcare institutions, pharmacies, and online channels. Its portfolio spans anti-infectives, respiratory/allergy, gastroenterology, pain management, dermatology, women's health, pediatrics, weight management, and medical cannabis therapeutic areas.

Product overview

Rafa Laboratories Ltd. (מעבדות רפא בע"מ) is an Israeli pharmaceutical company founded in 1937, specializing in the marketing, manufacturing, and distribution of originator medicines, generic drugs, prescription pharmaceuticals, over-the-counter (OTC) medicines, and therapeutic products. The company's product portfolio is organized into therapeutic categories spanning: anti-infectives (Coliracin, Itranol, Flucanol, Pen-Rafa VK, Monurol, Betadine); respiratory/allergy (Tesalin for allergic rhinitis); gastroenterology; pain management (Kalgaron lozenges, Nervo3 gel for neuropathic pain); dermatology and wound care (Betadine spray, Kelocote scar gel); women's health (Cimidona for menopause, Prefemin for PMS, Folex 400 for iron-deficiency anemia in pregnancy); medical cannabis (Axiban sublingual drops in 5 THC/CBD concentrations, IMC Medical Grade); pediatric health (Hedrin lice treatment line with gel, spray, mousse, and protect spray); and weight management (Epitomee Capsule). Rafa also operates a GMP-compliant manufacturing facility in Jerusalem and distributes its products across all healthcare institutions and pharmacies in Israel.

Differentiator

Problem solved

Functional benefit

Brands

  • Hedrin (הדרין): Product line for head lice treatment including gel, spray, and mousse variants.
  • Axiban (אקסיבן)
  • Tesalin (טסלין)
  • Monurol (מונורול)
  • Kelocote (קלו-קוט)
  • Prefemin (פרפמין)
  • Cimidona (סימידונה)
  • Kalgaron (קלגרון)
  • Betadine (בטאדין)
  • Nervo3 (נרבו 3)
  • Epitomee (אפיטומי)

Products and services

  • Coliracin (קולירצין) Antibiotic for treating infections caused by bacteria sensitive to colistin. Supplied as powder for infusion concentrate, containing 1,000,000 units of colistimethate sodium per vial. For healthcare institutions.
  • Itranol (איטרנול) Antifungal medication in capsule form (itraconazole 100 mg) for treating fungal infections of the mouth, throat, esophagus, vagina, skin, and nails, and systemic mycosis. For healthcare institutions and patients.
  • Flucanol (פלוקנול) Antifungal medication in capsules (fluconazole 50/100/150/200 mg) for treating a broad range of fungal infections including cryptococcal meningitis, candidiasis, oral/vaginal thrush, skin fungal infections, and for prevention of fungal infections in immunocompromised patients.
  • Pen-Rafa VK 500 (פן-רפא וי-ק 500) Penicillin-based antibiotic in capsules (penicillin V as potassium 500 mg) for treating infections caused by penicillin-sensitive bacteria. For healthcare institutions and patients.
  • Betadine Topical Spray (בטאדין תרסיס לשימוש חיצוני) Topical powder spray antiseptic (povidone iodine 2.5%) for skin disinfection, treatment and prevention of infections from burns, cuts, and surgical wounds. Non-stinging, creates a dry layer. OTC product for consumers.
  • Monurol (מונורול) Antibiotic powder (fosfomycin trometamol 3 g) for treating acute uncomplicated cystitis in women and adolescent girls, and for preventive antibiotic treatment prior to transrectal prostate biopsy in adult men. Prescription drug for healthcare institutions and patients.
  • Kalgaron (קלגרון) Sore throat lozenges (cetylpyridinium chloride 1.25 mg and lidocaine hydrochloride 1 mg) for relief of severe sore throat and oral/pharyngeal infections. Available in strawberry, mint, and orange flavors. For adults and children from age 6. OTC consumer product.
  • Cimidona 6.5 mg (סימידונה 6.5 מ"ג) Tablet containing 6.5 mg of black cohosh (Cimicifuga) dry extract for relief of menopausal symptoms including hot flashes, excessive sweating, sleep disturbances, irritability, and depressive mood. OTC product for consumers.
  • Cimidona Forte 13 mg (סימידונה פורטה 13 מ"ג) Tablet containing 13 mg of black cohosh (Cimicifuga) dry extract for relief of menopausal symptoms including hot flashes, excessive sweating, sleep disturbances, irritability, and depressive mood. Prescription drug for healthcare institutions and patients.
  • Prefemin (פרפמין) Tablet containing 20 mg of Agnus Castus (Agni Casti) dry extract for treatment of premenstrual syndrome (PMS) in women over 18. Hormone-free; relieves both emotional and physical PMS symptoms including mood changes, irritability, headaches, and breast congestion. OTC product for consumers.
  • Folex 400 (פולקס 400) Tablets containing ferrous fumarate 100 mg and folic acid 400 mcg for prevention and treatment of iron-deficiency anemia and maintenance of folic acid levels, especially during pregnancy. OTC product for consumers.
  • Tesalin (טסלין) Tablet containing 8 mg of petasins extracted from Petasites hybridus leaves for treatment of allergic rhinitis (hay fever) symptoms and associated eye, nose, and throat symptoms. Free of steroids and antihistamines, non-sedating, suitable from age 12. OTC product for consumers.
  • Axiban (אקסיבן) Medical cannabis product in full extract form with precise, standardized THC and CBD concentrations. Available as sublingual drops in 5 concentration combinations (T15/C3, T10/C10, T3/C15, T1/C20, T22/C4), each bottle containing 10 grams total. Requires a medical cannabis license. Manufactured under IMC Medical Grade standards. For licensed medical cannabis patients.
  • Epitomee Capsule (קפסולת אפיטומי) Capsule for weight management in adults with overweight or obesity (BMI 25-40 kg/m²), used in combination with a balanced diet and physical exercise. Works via a mechanical mechanism (no active pharmaceutical ingredient). OTC consumer product.
  • Hedrin Product Line (הדרין) Complete line of OTC products for the treatment and prevention of head lice. Includes: Hedrin ONCE Gel (15-minute single-treatment for short to medium hair), Hedrin ONCE Spray (for long/curly hair), Hedrin & Go Mousse (no immediate shampooing required), Hedrin Protect Spray (lice prevention, clinically proven), and Hedrin Wash Shampoo. All based on a physical mode of action without chemical pesticides, approved from age 6 months. For consumers and parents.
  • Kelocote Product Line (קלו-קוט) Silicone gel-based scar treatment product line. Includes: Kelocote Gel Tube (for all scar types except depressed scars), Kelocote Gel Spray (for widespread or touch-sensitive scars), and Kelocote UV Gel (with sun protection). Softens, flattens, and reduces redness of raised scars; relieves itch, pain, and discomfort. Clinically proven; recommended by physicians and pharmacists. For consumers and healthcare institutions.
  • Nervo3 Gel (נרבו 3 ג'ל) Topical gel for treatment of neuropathic symptoms (damage to the peripheral nervous system) of inflammatory, metabolic, or infectious origin. Contains a stabilized ozone formulation in oleic acid with alpha-lipoic acid, vitamin E acetate, capsicum extract, and essential amino acids. Clinically proven; available without prescription. For consumers and healthcare institutions.

Companies that use Rafa Laboratories Ltd.

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles3 records

Rafa Laboratories Ltd. technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Rafa Laboratories Ltd. partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered core and minor.

  • ExCEEd OrphancoreStrategic or Co-development Partner · 1 August 2022Rafa Laboratories is acquiring a significant stake in ExCEEd Orphan to improve its capabilities and expand its portfolio in medicines for rare diseases in CEE (Central and Eastern Europe) and Israel. The collaboration aims to bring new orphan drugs to these markets, driven by increasing demand and growth in the global orphan drug market. The partnership reflects Rafa's strategy to become an international player in this niche sector.
  • PanaxiacoreTechnology or IntegrationPanaxia is the manufacturer producing medical cannabis products for Rafa. Panaxia received Ministry of Health license to manufacture medical cannabis pharmaceutical products under GMP conditions and manufactures and sells medical cannabis products in various countries including the USA.
  • EpitomeeminorChannel Partner/ Reseller/ DistributorEpitomee capsule for weight management distributed by Rafa in Israel. Medical device/cosmetic product for adults with overweight or obesity (BMI 25-40 kg/m²) in combination with diet and physical activity.
  • FAES FARMAminorChannel Partner/ Reseller/ DistributorInternational pharmaceutical company whose products are distributed by Rafa in the Israeli market.
  • FALKminorChannel Partner/ Reseller/ DistributorInternational pharmaceutical company whose products are distributed by Rafa in the Israeli market.
  • HELSINNminorChannel Partner/ Reseller/ DistributorInternational pharmaceutical company whose products are distributed by Rafa in the Israeli market.
  • ONY BiotechminorChannel Partner/ Reseller/ DistributorBiotechnology company whose products are distributed by Rafa in the Israeli market.
  • SinclairminorChannel Partner/ Reseller/ DistributorInternational pharmaceutical company whose products are distributed by Rafa in the Israeli market.
  • T&RminorChannel Partner/ Reseller/ DistributorInternational pharmaceutical company whose products are distributed by Rafa in the Israeli market.
  • United TherapeuticsminorChannel Partner/ Reseller/ DistributorInternational pharmaceutical company focused on pulmonary hypertension whose products are distributed by Rafa in the Israeli market.
  • ZambonminorChannel Partner/ Reseller/ DistributorInternational pharmaceutical company whose products are distributed by Rafa in the Israeli market.
  • ZellerminorChannel Partner/ Reseller/ DistributorInternational pharmaceutical company whose products are distributed by Rafa in the Israeli market.
  • Maccabi Healthcare ServicescoreStrategic or Co-development PartnerRafa and Maccabi Yozmot and Management signed an agreement for supply of quality medical cannabis products from Rafa to Maccabi Healthcare members. The products are delivered directly to Maccabi members' homes, making Rafa the first Israeli pharmaceutical company to implement the medical cannabis reform.

Scale indicators2 records

Recent moves6 records

Expansion highlights3 records

Rafa Laboratories Ltd. competitors and assessment

Company assessment

Direct peers

  • Teva Pharmaceutical Industries: Israel's largest pharmaceutical company and the world's leading generic drug manufacturer. Directly comparable to Rafa as a domestic Israeli pharma with branded generics, OTC, and specialty portfolios, though operating at much larger global scale.
  • Taro Pharmaceutical Industries: Israel-based generic pharmaceutical manufacturer with a focus on branded generics, OTC, and prescription products. Direct competitor in the Israeli generic pharma space with overlapping therapeutic categories such as dermatology and anti-infectives.
  • Dexcel Pharma: Israeli specialty pharmaceutical company developing and marketing branded generic and innovative medicines. Comparable mid-sized peer with a similar Israel-centric go-to-market model and therapeutic breadth.
  • Panaxia Pharmaceutical Industries: Israeli pharmaceutical-grade medical cannabis manufacturer that produces Axiban for Rafa under GMP. Comparable in the cannabis-pharma intersection with overlapping manufacturing standards (IMC Medical Grade, GMP).
  • Helsinn Healthcare: Swiss specialty pharmaceutical company focused on cancer supportive care and rare diseases. Already partners with Rafa for Israeli distribution; comparable as a mid-size specialty pharma expanding through regional partnerships.
  • FAES Farma: Spanish pharmaceutical company with branded generics, OTC, and specialty products. Distributes through Rafa in Israel and shares a comparable mid-cap specialty pharma profile with international partnership-driven growth.
  • Zambon: Italian multinational pharmaceutical company with focus on respiratory, pain, and women's health. Comparable to Rafa's therapeutic portfolio breadth and partnership-based international expansion model.

Regional players

  • Trima (Teva Israel legacy brands): Israeli pharmaceutical manufacturer and marketer focused on generic and branded generic products distributed across Israeli pharmacies. Comparable in therapeutic scope and channel strategy to Rafa's portfolio.

Broad incumbents

  • Perrigo Company: Global leader in consumer self-care products and generic pharmaceuticals with strong OTC and store-brand portfolios. Comparable to Rafa's OTC and consumer health segments (e.g., Hedrin, Kalgaron, Betadine, Tesalin).
  • United Therapeutics: U.S. biotechnology company specializing in pulmonary hypertension products distributed by Rafa in Israel. Comparable therapeutic-area overlap in respiratory and pulmonary arterial hypertension.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Rafa Laboratories Ltd. social profiles

Digital presence

Rafa Laboratories Ltd. compliance and trust

Trust signal

Compliance2 records

Rafa Laboratories Ltd. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Rafa Laboratories Ltd. leadership team

Management profile

Number of profiles

Profiles3 records

Rafa Laboratories Ltd. funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Rafa Laboratories Ltd. M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rafa Laboratories Ltd.

What does Rafa Laboratories Ltd. do?

Rafa Laboratories is an Israeli pharmaceutical company that manufactures, markets, and distributes a broad portfolio of originator drugs, generic medicines, prescription pharmaceuticals, OTC products, and medical cannabis products. The company operates a GMP-compliant manufacturing facility in Jerusalem compliant with European EMA regulations and distributes products across all Israeli healthcare institutions, pharmacies, and online channels. Its portfolio spans anti-infectives, respiratory/allergy, gastroenterology, pain management, dermatology, women's health, pediatrics, weight management, and medical cannabis therapeutic areas.

Is Rafa Laboratories Ltd. a public or private company?

Rafa Laboratories Ltd. is a private company. It is classified as family owned and is currently operating.

When was Rafa Laboratories Ltd. founded?

Rafa Laboratories Ltd. was founded in 1937. It employs 101 to 250 people.

Where is Rafa Laboratories Ltd. based?

Rafa Laboratories Ltd. is headquartered in Jerusalem, Israel, in the Middle East region.

How does Rafa Laboratories Ltd. make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Rafa Laboratories Ltd.'s main competitors?

Direct peers on record are Teva Pharmaceutical Industries, Taro Pharmaceutical Industries, Dexcel Pharma, Panaxia Pharmaceutical Industries, Helsinn Healthcare, FAES Farma and Zambon. Trima (Teva Israel legacy brands) is listed as a regional player. Broad incumbents are Perrigo Company and United Therapeutics.

Does Rafa Laboratories Ltd. have an API?

No public API is recorded for Rafa Laboratories Ltd..

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
CTechRafa signs $82.5 million U.S. defense agreement for emergency drug injectorsRafa signed a framework agreement with the U.S. Defense Logistics Agency to supply auto-injectors containing Midazolam over five years, with potential purchases rising to $257 million. The deal includes one year of performance and four option years, with a minimum commitment of $47.5 million.Investing.comRafa Laboratories Share Price | RAFA Stock - Investing.com UKThe article reports that Rafa Laboratories Limited's stock is currently trading at 0.00 ILS on the Tel Aviv Stock Exchange, with no recent activity or significant market data available. It provides information about the stock, its trading status, and related analysis tools, but no recent price change or operational details are given.GlobesRafa Laboratories plans IPO at NIS 2.2b valuationRafa Laboratories, a pharmaceutical company, is planning an IPO on the Tel Aviv Stock Exchange at an estimated valuation of NIS 2-2.4 billion. The company's owners will sell 30-50% of shares for up to NIS 1.1 billion, with controlling shareholder FIMI potentially receiving over NIS 1 billion in proceeds.GlobesEpitomee Medical's slimming pill approved in EuropeEpitomee Medical received EU approval for its weight-loss capsule, removing the final barrier to European marketing. A German distributor committed to ordering $5.3 million over 12 months, with $110,000 for immediate delivery. The company expects to fill the immediate order soon, subject to security in Israel.PR NewswireRafa Laboratories Awarded up to $186 Million by BARDA to Develop a Life-Saving Intramuscular TXA Injection for Prehospital CareRafa Laboratories, an Israeli biodefense company, has been awarded a contract worth up to $186 million by BARDA, the U.S. Biomedical Advanced Research and Development Authority, for developing a novel intramuscular formulation of tranexamic acid for prehospital hemorrhage treatment. The injection, designed for use with an autoinjector, aims to simplify emergency bleeding control in trauma situations where traditional IV administration is impractical. The development program includes formulation work, manufacturing scale-up, clinical trials, and seeks FDA approval.GlobeNewswireMithra and Rafa Laboratories sign binding Head of Terms to commercialize DONESTA® in IsraelMithra and Rafa Laboratories signed a binding Head of Terms to commercialize DONESTA in Israel, with Rafa receiving exclusive rights. Mithra is eligible for EUR 2.05 million in sales-related milestones and tiered royalties. The final license and supply agreement is planned for Q1 2024.PR NewswireU.S. VERTEIDIGUNGSMINISTERIUM ERTEILT RAFA LABORATORIES PRODUCTION EINE NACHFOLGEVEREINBARUNG ÜBER MEHR ALS 45 MILLIONEN USDRafa Laboratories Ltd. was awarded a follow-on production agreement exceeding $45 million by the U.S. Department of Defense's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to manufacture and deliver 10 mg Midazolam Autoinjectors under the Advanced Anticonvulsant System (AAS). The product, developed in Israel and manufactured in Jerusalem, is the first market-available autoinjector for treating status epilepticus, including seizures resulting from nerve agent exposure, and is already sold to NATO member states for emergency use. This agreement follows a prior prototype agreement (W911QY2090014) that led to FDA approval of the Midazolam Autoinjector in 2022, and builds on Rafa's previous collaboration with JPEO-CBRND on the Atropin Autoinjektor introduced in the U.S. in 2017.PR NewswireU.S. Department of Defense Awards Rafa Laboratories Production FOLLOW-ON Agreement of over $45 millionRafa Laboratories LTD. was awarded a follow-on production agreement worth over $45 million from the U.S. Department of Defense's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) for the Advanced Anticonvulsant System (AAS) - Midazolam autoinjector. The 10mg Midazolam Injection autoinjectors, indicated for treating status epilepticus and nerve agent-induced seizures, have been manufactured and delivered to the Joint Force since December 2022. The product was developed and is manufactured at Rafa's facility in Jerusalem, Israel, and this agreement follows FDA approval of the device in 2022 as well as prior collaboration on an atropine autoinjector launched in the U.S. in 2017.PR NewswireU.S. Department of Defense Awards Rafa Laboratories Production FOLLOW-ON Agreement of over $45 millionThe U.S. Department of Defense awarded Rafa Laboratories a follow-on production agreement valued at over $45 million for its Advanced Anticonvulsant System (AAS) Midazolam autoinjectors. This contract follows the initial prototype development and FDA approval, with deliveries to the Joint Force commencing in December 2022 to treat seizures from nerve agent exposure. The product, manufactured in Israel, is designed to replace older diazepam autoinjectors and offers faster administration in emergency field settings.ExceedorphanRafa Laboratories to acquire a significant stake in ExCEEd Orphan and expand its international capabilities in medicines addressing rare diseasesRafa Laboratories announced a strategic collaboration and investment in ExCEEd Orphan to expand its capabilities in rare disease medicines across Central and Eastern Europe and Israel. The partnership aims to strengthen market access and bring new orphan drugs to these regions, capitalizing on a growing global orphan drug market.